fruquintinib
hutchmed
['colorectal', 'fresco-2', 'rectal']
 at #esmo22, and co-authored presented findings from the fresco-2 clinical trial, which offers a very promising treatment alternative for individuals with refractory metastatic colorectal cancer.
Leading translational research to accelerate & advance personalized and targeted therapies against cancer. 
@iCERCA centre